Compass Therapeutics to Participate in the J.P. Morgan 2026 Healthcare Conference

About this update from Compass, Inc.

[{"type":"image","alt":"Compass Therapeutics","displaySize":"","headline":null,"caption":"Compass Therapeutics","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":78,"url":"https://media.zenfs.com/en/globenewswire.com/24acefcca952f8de468624053ca6bd5b"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/AUo7dD10RyaiaUtTlrJJIA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTEwOTtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/24acefcca952f8de468624053ca6bd5b","width":300,"height":78}},"lazy":false},{"type":"text","content":"BOSTON, Dec. 17, 2025 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics, today announced that the Company will present at the J.P. Morgan 2026 Healthcare Conference on January 14, 2026.","length":310,"tagName":"p"},{"type":"text","content":"Presentation DetailsDate: Wednesday, January 14, 2026 Time: 7:30 AM PT Webcast Link: cmpx.info/jpmorgan","length":106,"tagName":"p"},{"type":"text","content":"Virtual/Replay availability: The presentation will be archived on Compass’ Events page.","length":102,"tagName":"p"},{"type":"text","content":"Investors interested in scheduling one-on-one meetings with Compass on January 14, 2026 should contact their J.P. Morgan representative.","length":136,"tagName":"p"},{"type":"text","content":"Compass will also host investor meetings as part of the LifeSci Partners Corporate Access Event, January 12 & 13, 2026 in San Francisco, CA. Interested investors should contact their LifeSci representative to request a meeting. ","length":232,"tagName":"p"},{"type":"text","content":"About Compass TherapeuticsCompass Therapeutics, Inc. is a clinical-stage oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. The company’s scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth. Compass has built a robust pipeline of novel product candidates designed to target multiple critical biological pathways required for an effective anti-tumor response. These pathways include modulation of the microvasculature via angiogenesis-targeted agents, induction of a potent immune response via activators on effector cells in the tumor microenvironment, a...

More updates from Compass, Inc.